Focused On-demand Library for tRNA-splicing endonuclease subunit Sen2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8NCE0

UPID:

SEN2_HUMAN

Alternative names:

tRNA-intron endonuclease Sen2

Alternative UPACC:

Q8NCE0; B7Z6K1; C9IZI7; G5E9Q3; Q8WTW7; Q9BPU7

Background:

The tRNA-splicing endonuclease subunit Sen2 plays a pivotal role in cellular function by ensuring the proper splicing of precursor tRNA, a critical step in the maturation of tRNA molecules necessary for protein synthesis. This enzyme, also known as tRNA-intron endonuclease Sen2, is integral to the tRNA-splicing endonuclease complex, facilitating the precise cleavage of pre-tRNA to release introns and form mature tRNA molecules. Its activity is essential for maintaining the fidelity of protein translation and overall cellular health.

Therapeutic significance:

Given its crucial role in tRNA splicing, mutations in the gene encoding tRNA-splicing endonuclease subunit Sen2 are linked to Pontocerebellar hypoplasia 2B, a severe neurological disorder. Understanding the role of tRNA-splicing endonuclease subunit Sen2 could open doors to potential therapeutic strategies for this debilitating condition, highlighting the importance of targeted research in uncovering novel treatment avenues.